- Home
- CSTL vs DIN Comparison
CSTL vs DIN Comparison
Compare CSTL & DIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- DIN
- Stock Information
- Founded
- CSTL 2007
- DIN 1958
- Country
- CSTL United States
- DIN United States
- Employees
- CSTL N/A
- DIN N/A
- Industry
- CSTL Medical Specialities
- DIN Restaurants
- Sector
- CSTL Health Care
- DIN Consumer Discretionary
- Exchange
- CSTL Nasdaq
- DIN Nasdaq
- Market Cap
- CSTL 561.9M
- DIN 379.1M
- IPO Year
- CSTL 2019
- DIN 1991
- Fundamental
- Price
- CSTL $16.23
- DIN $23.06
- Analyst Decision
- CSTL Strong Buy
- DIN Hold
- Analyst Count
- CSTL 6
- DIN 9
- Target Price
- CSTL $37.67
- DIN $26.86
- AVG Volume (30 Days)
- CSTL 370.3K
- DIN 335.1K
- Earning Date
- CSTL 08-04-2025
- DIN 08-06-2025
- Dividend Yield
- CSTL N/A
- DIN 8.79%
- EPS Growth
- CSTL N/A
- DIN N/A
- EPS
- CSTL N/A
- DIN 3.61
- Revenue
- CSTL $347,083,000.00
- DIN $820,851,000.00
- Revenue This Year
- CSTL N/A
- DIN $8.62
- Revenue Next Year
- CSTL $1.36
- DIN $1.82
- P/E Ratio
- CSTL N/A
- DIN $6.43
- Revenue Growth
- CSTL 38.43
- DIN N/A
- 52 Week Low
- CSTL $15.45
- DIN $18.63
- 52 Week High
- CSTL $35.84
- DIN $37.44
- Technical
- Relative Strength Index (RSI)
- CSTL 33.76
- DIN 40.67
- Support Level
- CSTL $16.00
- DIN $22.70
- Resistance Level
- CSTL $16.65
- DIN $26.48
- Average True Range (ATR)
- CSTL 0.76
- DIN 0.89
- MACD
- CSTL -0.30
- DIN -0.12
- Stochastic Oscillator
- CSTL 5.40
- DIN 9.52
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About DIN Dine Brands Global Inc.
Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.